Lakefront Biotherapeutics (LKFT) Net Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Net Margin of 223.61% for Q1 2026, up 42821.0% year-on-year from N/an in Q1 2025, and up 157.54% on a QoQ basis from 86.83% in Q4 2025.
Lakefront Biotherapeutics (LKFT) Net Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Net Margin for 13 consecutive years, with 223.61% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 42821.0% year-over-year to 223.61% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.38% (up 15200.0% YoY) and the FY2025 annual result came in at 28.85%, up 197.0% from the prior year.
- Net Margin improved to 223.61% in Q1 2026 per LKFT's latest filing, from 86.83% in the prior quarter.
- Over the last five years, Net Margin for LKFT reached as high as 223.61% in Q1 2026 and fell as low as 204.6% in Q1 2025.
- A 5-year average of 26.21% and a median of 8.48% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin jumped 260706 bps — and 2025, when it slumped 34911 bps.
- Year by year, Net Margin stood at 114.63% in 2022, then soared by 222 bps to 140.3% in 2023, then soared by 57 bps to 220.06% in 2024, then slumped by 61 bps to 86.83% in 2025, then jumped by 158 bps to 223.61% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 223.61%, 86.83%, and 2.65% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | 223.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 223.61% |
| Dec 31, 2025 | 86.83% |
| Sep 30, 2025 | 2.65% |
| Jun 30, 2025 | -1.99% |
| Mar 31, 2025 | -204.60% |
| Dec 31, 2024 | 220.06% |
| Sep 30, 2024 | -26.70% |
| Jun 30, 2024 | -17.55% |
| Mar 31, 2024 | 144.51% |
| Dec 31, 2023 | 140.30% |
| Sep 30, 2023 | 42.23% |
| Jun 30, 2023 | 8.48% |
| Mar 31, 2023 | 39.62% |
| Dec 31, 2022 | -114.63% |
| Sep 30, 2022 | 85.75% |
| Jun 30, 2022 | -90.66% |
| Mar 31, 2022 | -92.36% |
| Dec 31, 2021 | -24.08% |
| Sep 30, 2021 | -2,521.31% |
| Jun 30, 2021 | -46.02% |